Lumenis EMEA (Europe, Middle East, Africa) Headquarters have announced its recent listing of Lumenis Ltd. shares on the NASDAQ under the ticker ‘LMNS’. The company returned to the NASDAQ on 27 February, issuing 6.3 million shares at $12 per share.
The return to the stock exchange is aligned with Lumenis’ positioning as a world leader and expert in developing and commercialising innovative energy-based technologies for aesthetic, surgical and ophthalmic markets.
Trading on the NASDAQ will enable Lumenis to magnify its already sound investments into R&D, constantly delivering innovative products to its customers all over the globe.
At the biggest spring congresses of Europe and Middle East, including the 12th Anti-Aging Medicine World Congress (AMWC) Monaco, Cosmoprof Bologna and Dubai Derma, Lumenis launched three new aesthetic products: the laser hair reduction products LightSheer® DESIRE™ and LightSheer® INFINITY™, and the new Q-Switched Nd:YAG module for the M22™ multi-application platform for the treatment of over 30 skin conditions and hair removal.
In addition to the new products’ offerings, 2014 is marked by the opening of a direct Lumenis sales office in the UK and strengthening of its offices in Germany and Italy, through the employment of larger sales and marketing teams.
For years, Lumenis’ ground-breaking products have redefined medical treatments and have set a number technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designing advanced technologies that have revolutionised existing treatment methods in each and every one of the verticals in which it operates.
